natgillin/translations-raw huggingface dataset:
Patients were enrolled in the studies on the basis of extreme short stature, slow growth rates, low IGF-1 serum concentrations, and normal GH secretion.
Bolniki so bili vključeni v študije na osnovi ekstremno nizke telesne višine, počasne rasti, nizkih koncentracij IGF-1 v serumu in normalnega izločanja GH.
Patients were enrolled into 4 groups (see section 5.1).
Bolnike so vključili v 4 skupine (glejte poglavje 5.1).
Patients were enrolled with CD4 counts
Bolnice so imele ob sprejemu v raziskavo število CD4 < 250 celic/mm3, bolniki pa
Patients were excluded from participation in IMBRUVICA phase 2 and 3 studies if they required warfarin or other vitamin K antagonists.
Bolniki, ki so morali jemati varfarin ali katerega od drugih antagonistov vitamina K, niso bili vključeni v študije faze 2 in 3 zdravila IMBRUVICA.
Patients were excluded from the study if there was a presence of invasive oesophageal cancer, if they had a history of cancer other than non- melanoma skin cancer or if they had received prior PDT to the oesophagus.
Bolnike so izključili iz raziskave, če so imeli invazivni rak požiralnika, rak v anamnezi, razen kožnega raka, ki ni bil melanom, ali če so poprej dobili PDT v požiralnik.
Patients were exposed to study drug for a mean of 14 months.
Povprečna starost je bila 56,9 leta, 89,8 % randomiziranih bolnikov pa je imelo neizzvane dogodke VTE.
Patients were given a 96-hour constant rate infusion of Xigris at 24 g/kg/hr (n=850) or placebo (n=840).
Bolniki so prejeli 96-urno infuzijo zdravila Xigris s stalno hitrostjo v odmerku 24 g/kg/h (n = 850) ali placebo (n = 840).
Patients were given Blincyto for up to five treatment cycles.
Bolniki so prejeli do pet ciklusov zdravljenja z zdravilom Blincyto.
Patients were given either 2 mg/kg or 3 mg/kg Strensiq three times a week for 24 weeks.
Bolniki so prejemali 2 mg/kg ali 3 mg/kg zdravila Strensiq trikrat na teden, kar je trajalo 24 tednov.
Patients were given either a 700 microgram or a 350 microgram implant of Ozurdex or they received a sham treatment.
Bolniki so prejeli zdravilo Ozurdex v 700-mikrogramskem ali 350-mikrogramskem vsadku ali pa navidezno zdravljenje.
Patients were given Kineret at a starting dose of 1 to 2 mg per kg body-weight daily, increased after a month if necessary.
Bolniki so prejemali zdravilo Kineret v začetnem odmerku 1 do 2 mg na kg telesne mase dnevno, po mesecu dni pa se je ta odmerek po potrebi povečal.
Patients were given up to 6 injections at 1-month intervals and were followed up for 3 years from the first injection.
Bolnikom so dali največ 6 injekcij v 1-mesečnih intervalih in jih spremljali 3 leta od prve injekcije.
Patients were in WHO functional class I (n = 19 patients, 29 %), class II (n = 27 patients, 42%) or class III (n = 18 patients, 28%) at start of study treatment.
Bolniki so bili ob začetku zdravljenja po klasifikacji SZO v funkcijskem razredu I (n = 19 bolnikov, 29 %), razredu II (n = 27 bolnikov, 42 %) ali razredu III (n = 18 bolnikov, 28 %).
Patients were ineligible if there was planned use of a P2Y12 receptor antagonist, dipyridamole, cilostazol, or anticoagulant therapy during the study period; if they had a bleeding disorder or a history of an ischaemic stroke or intracranial bleeding, a central nervous system tumour, or an intracranial vascular abnormality; if they had had gastrointestinal bleeding within the previous 6 months or major surgery within the previous 30 days.
Bolniki niso bili primerni, če so imeli načrtovano uporabo antagonista receptorjev P2Y12, dipiridamola, cilostazola ali antikoagulantov med obdobjem študije; če so imeli motnjo strjevanja krvi ali anamnezo ishemične možganske kapi ali intrakranialne krvavitve, tumor osrednjega živčevja ali intrakranialno žilno nepravilnost; če so imeli gastrointestinalno krvavitev v zadnjih 6 mesecih ali večjo operacijo v zadnjih 30 dneh.
Patients were instructed to take 1 dose of study medication approximately 30 minutes prior to initiation of sexual activity.
Bolniki so morali vzeti 1 odmerek preučevanega zdravila približno 30 minut pred začetkom spolnega odnosa.
Patients were maintained on study treatments until there was PSA progression (confirmed 25% increase over the patient’s baseline/nadir) together with protocol-defined radiographic progression and symptomatic or clinical progression.
Bolniki so prejemali študijsko zdravljenje dokler se je koncentracija PSA zviševala (potrjeno zvišanje za 25% od izhodiščne/najnižje vrednosti pri bolniku), pri tem pa gre hkrati za radiografsko potrjeno in simptomatsko ali klinično napredovanje bolezni.
Patients were not allowed to receive supplemental levodopa or catechol-O-methyl transferase (COMT) inhibitors.
Bolniki niso smeli prejemati dodatne levodope ali zaviralcev katehol-O-metil-transferaze.
Patients were not allowed to receive supplemental levodopa/carbidopa or catechol-O-methyl transferase (COMT) inhibitor medicinal products during the trial.
Bolniki med preskušanjem niso smeli prejemati dodatne levodope/karbidope ali zaviralcev katehol-O-metil- transferaze.
Patients were not genotyped to separate into ADPKD type 1 and 2 and it is not known whether Jinarc has comparable efficacy in these subgroups.
Bolniki niso bili genotipizirani za razdelitev v tip 1 in 2 ADPKD, zato ni znano, ali je zdravilo Jinarc v teh podskupinah primerljivo učinkovito.
Patients were not included if they had concomitant DVT or superficial- vein thrombosis within 3 cm of the sapheno-femoral junction.
Bolniki niso bili vključeni, če so imeli sočasno globoko vensko trombozo ali povrhnjo vensko trombozo , ki je bila bližje kot 3 cm od safeno- femoralnega spoja.
Patients were not required to show disease progression on docetaxel, as toxicity from this chemotherapy may have led to discontinuation.
Bolnikom ob zdravljenju z docetakselom ni bilo treba kazati vidnih znakov napredovanja bolezni, ker je lahko že sama toksičnost te kemoterapije vodila v prekinitev zdravljenja.
Patients were observed off treatment for the occurrence of rebound (PASI 150% of baseline) and for the time to relapse (defined as a loss of at least half of the improvement achieved between baseline and week 24).
Bolnike so brez zdravljenja spremljali glede preobratnih znakov (PASI  150 % izhodiščnega) in časa do recidiva (opredeljenega kot izginotje vsaj polovice izboljšanja, doseženega med izhodiščem in 24. tednom).
Patients were prohibited from using laxatives other than bisacodyl rescue laxative if they had not had a bowel movement for 72 hours.
Bolniki niso smeli uporabljati drugih odvajal razen bisakodila, kot rešilnega odvajala, v primeru, da na blato niso šli več kot 72 ur.
Patients were randomised (1:1:1) to receive either placebo or Taltz (80 mg every two or four weeks [Q2W or Q4W] following a 160 mg starting dose) for 12 weeks.
Bolniki so bili randomizirani (1:1:1) za prejemanje placeba ali zdravila Taltz (80 mg vsaka dva ali štiri tedne [Q2W ali Q4W] po 160- miligramskem začetnem odmerku) 12 tednov.
Patients were randomised (1:1:1) to receive pembrolizumab at a dose of 2 (n=180) or 10 mg/kg (n=181) every
Bolnike so randomizirali (v razmerju 1:1:1) na zdravljenje s pembrolizumabom v odmerku
Patients were randomised (1:1:1) to receive pembrolizumab at a dose of 2 (n=344) or 10 mg/kg (n=346) every 3 weeks or docetaxel at a dose of 75 mg/m2 every 3 weeks (n=343) until disease progression or unacceptable toxicity.
Bolnike so randomizirali (v razmerju 1:1:1) za zdravljenje s pembrolizumabom v odmerku 2 (n = 344) ali 10 mg/kg (n = 346) na 3 tedne ali z docetakselom v odmerku 75 mg/m2 na tedne (n = 343) do napredovanja bolezni ali nesprejemljivih toksičnih sopojavov.
Patients were randomised (1:2:2:2) to receive either placebo, or Taltz (80 mg every two or four weeks [Q2W or Q4W] following a 160 mg starting dose) or etanercept 50 mg twice weekly for 12 weeks.
Bolniki so bili randomizirani (1:2:2:2) za prejemanje placeba ali zdravila Taltz (80 mg vsaka dva ali štiri tedne [Q2W ali Q4W] po 160- miligramskem začetnem odmerku) ali 50 mg etanercepta dvakrat na teden 12 tednov.
Patients were randomised 1:1 to receive Vectibix at a dose of 6 mg/kg given once every two weeks plus best supportive care (not including chemotherapy) (BSC) or BSC alone.
Bolniki so bili v razmerju 1:1 randomizirani bodisi na zdravljenje z zdravilom Vectibix v odmerku 6 mg/kg enkrat na dva tedna in najboljšo podporno oskrbo (BSC – Best Supportive Care) (kar ni vključevalo kemoterapije) bodisi na samo BSC.
Patients were randomised 2:1 to Jakavi versus best available therapy.
Bolnike so randomizirali v razmerju 2:1 tako, da so prejemali zdravilo Jakavi ali pa najboljše razpoložljivo zdravljenje.
Patients were randomised 2:1 to receive Tarceva 150 mg or placebo orally once daily.
Bolniki so bili randomizirani v razmerju 2 : 1 v skupino, ki je prejemala 150 mg zdravila Tarceva, in v skupino, ki je prejemala placebo peroralno enkrat na dan.
Patients were randomised in a 1:1 ratio to either switch to Descovy (n = 333), or stay on their baseline emtricitabine/tenofovir disoproxil fumarate containing regimen (n = 330).
Bolniki so bili randomizirani v razmerju 1:1 bodisi za prehod na zdravilo Descovy (n = 333) ali za nadaljevanje začetnega režima, ki je vseboval emtricitabin/dizoproksiltenofovirat fumarat (n = 330).
Patients were randomised in a 1:1 ratio to receive Cyramza plus paclitaxel (n=330) or placebo plus paclitaxel (n=335).
Bolniki so bili randomizirani v razmerju 1:1 za prejemanje zdravila Cyramza in paklitaksela (n=330) ali placeba in paklitaksela (n=335).
Patients were randomised in a 1:1 ratio to receive either atazanavir 300 mg with cobicistat 150 mg once daily or atazanavir 300 mg with ritonavir 100 mg once daily, each administered with a fixed background regimen containing tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg administered as a fixed-dose combination tablet.
Bolnike so randomizirali v razmerju 1:1 tako, da so prejemali atazanavir v odmerku 300 mg s kobicistatom v odmerku 150 mg enkrat na dan ali atazanavir v odmerku 300 mg z ritonavirjem v odmerku 100 mg enkrat na dan, oboje s fiksnim osnovnim režimom, ki je vključeval 300 mg dizoproksiltenofovirat fumarata in 200 mg emtricitabina v obliki tablete s fiksno kombinacijo.
Patients were randomised in a 1:1 ratio to treatment with Epclusa for 12 weeks or SOF+RBV for 12 weeks.
Bolniki so bili randomizirani v razmerju 1 : 1 za 12-tedensko zdravljenje z zdravilom Epclusa ali za 12-tedensko zdravljenje s SOF + RBV.
Patients were randomised in a 1:1 ratio to treatment with Epclusa for 12 weeks or SOF+RBV for 24 weeks.
Bolniki so bili randomizirani v razmerju 1 : 1 za 12-tedensko zdravljenje z zdravilom Epclusa ali za 24-tedensko zdravljenje s SOF + RBV.
Patients were randomised in a 1:1:1 ratio to treatment with Epclusa for 12 weeks, Epclusa + RBV for 12 weeks or Epclusa for 24 weeks.
Bolniki so bili randomizirani v razmerju 1 : 1 : 1 za 12-tedensko zdravljenje z zdravilom Epclusa, 12-tedensko zdravljenje z zdravilom Epclusa + RBV ali za 24- tedensko zdravljenje z zdravilom Epclusa.
Patients were randomised in a 2:1 ratio to either switch to FTC/RPV/TDF at baseline (n = 317), or SBR for 24 weeks (n = 159) before switching to FTC/RPV/TDF for an additional 24 weeks (Delayed Switch arm, n = 152).
Bolniki so bili randomizirani v razmerju 2:1 bodisi v skupino s prehodom na FTC/RPV/TDF na začetku (n = 317) ali v skupino, ki je ostala na svojem začetnem protiretrovirusnem režimu še 24. tednov (n = 159) pred prehodom na FTC/RPV/TDF za dodatnih 24 tednov (n = 152).
Patients were randomised in a 2:1 ratio to either switch to Stribild or stay on their baseline antiretroviral regimen (SBR) for 48 weeks.
Bolniki so bili randomizirani v razmerju 2:1 na bodisi prehod na zdravilo Stribild ali nadaljevanje svojega izhodiščnega protiretrovirusnega režima (SBR, baseline antiretroviral regimen) za 48 tednov.
Patients were randomised to either 230 mg lopinavir/57.5 mg ritonavir per m2 or 300 mg lopinavir/75 mg ritonavir per m2.
Bolnike so randomizirali bodisi na 230 mg lopinavirja/57,5 mg ritonavirja na m2 ali 300 mg lopinavirja/75 mg ritonavirja na m2.
Patients were randomised to either placebo (N = 582) or selexipag (N = 574) twice daily.
Bolniki so bili randomizirani za prejemanje placeba (N = 582) ali seleksipaga (N = 574) dvakrat na dan.
Patients were randomised to one of five treatment groups (tadalafil 2.5 mg, 10 mg, 20 mg, 40 mg, or placebo).
Bolnike so randomizirali v eno od petih skupin obravnave: (2,5 mg, 10 mg, 20 mg, 40 mg tadalafila ali placebo).
Patients were randomised to one of four treatment groups: placebo, sildenafil 20 mg, sildenafil 40 mg or sildenafil 80 mg, three times a day.
Bolnike so randomizirali na eno od štirih vrst obravnave: placebo, sildenafil 20 mg, sildenafil 40 mg ali sildenafil 80 mg trikrat na dan.
Patients were randomised to paclitaxel alone (90 mg/m2 IV over 1 hour once weekly for three out of four weeks) or in combination with Avastin (10 mg/kg IV infusion every two weeks).
Bolniki so bili randomizirani v skupino, ki je prejemala le paklitaksel (90 mg/m2 i.v. v 1 uri enkrat tedensko tri od štirih tednov) ali v skupino, ki je prejemala kombinacijo paklitaksela in zdravila Avastin (10 mg/kg z intravensko infuzijo vsaka dva tedna).
Patients were randomised to platinum-based chemotherapy (paclitaxel 200 mg/m2) and carboplatin AUC = 6.0, both by IV infusion (PC) on day 1 of every 3-week cycle for up to 6 cycles or PC in combination with Avastin at a dose of 15 mg/kg IV infusion day 1 of every 3-week cycle.
Randomizirani bolniki so na dan 1 vsakega tritedenskega cikla do skupno 6 ciklov prejeli kemoterapijo na osnovi platine (paklitaksel 200 mg/m2 in karboplatin AUC = 6,0, oboje z i.v. infuzijo) ali kemoterapijo na osnovi platine v kombinaciji z zdravilom Avastin v odmerku 15 mg/kg v obliki intravenske infuzije na dan 1 vsakega tritedenskega cikla.
Patients were randomised to platinum-based chemotherapy, cisplatin 80 mg/m2 intravenous infusion on day 1 and gemcitabine 1250 mg/m2 intravenous infusion on days 1 and 8 of every 3-week cycle for up to 6 cycles (CG) with placebo or CG with Avastin at a dose of 7.5 or 15 mg/kg IV infusion day 1 of every 3-week cycle.
Randomizirani bolniki so prejeli kemoterapijo na osnovi platine, cisplatin 80 mg/m2 v obliki intravenske infuzije na dan 1 in gemcitabin 1250 mg/m2 v obliki intravenske infuzije na dneva 1 in 8 vsakega tritedenskega cikla do skupno 6 ciklov ali cisplatin in gemcitabin v kombinaciji z zdravilom Avastin v odmerku 7,5 ali 15 mg/kg v obliki intravenske infuzije na dan 1 vsakega tritedenskega cikla.
Patients were randomised to receive a single dose of Humira 40 mg/0.8 ml or Humira 40 mg/0.4 ml, followed by a single injection of the opposite treatment at their next dose.
Bolniki so bili randomizirani tako, da so prejeli enkraten odmerek zdravila Humira 40 mg/0,8 ml ali Humira 40 mg/0,4 ml, ki mu je pri naslednjem odmerku sledila ena injekcija nasprotnega zdravljenja.
Patients were randomised to receive either oral lapatinib 1,000 mg once daily plus trastuzumab 4 mg/kg administered as an intravenous (IV) loading dose, followed by 2 mg/kg IV weekly (N = 148), or oral lapatinib 1,500 mg once daily (N = 148).
Bolnice so randomizirali ali na prejemanje peroralnega lapatiniba 1.000 mg enkrat na dan in trastuzumaba 4 mg/kg, uporabljenega kot intravenski (i.v.) polnilni odmerek, ki mu je sledil odmerek 2 mg/kg i.v. vsak teden (N = 148), ali na prejemanje peroralnega lapatiniba 1.500 mg enkrat na dan (N = 148).
Patients were randomised to receive either SPRYCEL 100 mg once daily or imatinib 400 mg once daily.
Bolniki so bili randomizirani tako, da so prejemali bodisi zdravilo SPRYCEL v odmerku 100 mg enkrat na dan ali imatinib v odmerku 400 mg enkrat na dan.
Patients were randomised to receive either tacrolimus ointment (0.1% adults; 0.03% children) or vehicle, once a day twice weekly on Mondays and Thursdays.
Bolnike so randomizirali ali na uporabo mazila s takrolimusom (0,1 % odrasli, 0,03 % otroci) ali vehikla enkrat na dan in dvakrat na teden, ob ponedeljkih in četrtkih.
Patients were randomised to receive either Tyverb 1250 mg once daily (continuously) plus capecitabine (2000 mg/m2/day on days 1-14 every 21 days), or to receive capecitabine alone (2500 mg/m2/day on days 1-14 every 21 days).
Bolniki so bili randomizirani tako, da so prejemali bodisi zdravilo Tyverb v odmerku 1.250 mg enkrat na dan (neprekinjeno) in kapecitabin (2.000 mg/m2/dan od 1.do 14. dne 21-dnevnega ciklusa) ali pa samo kapecitabin (2.500 mg/m2/dan na 1.-14. dan 21-dnevnega ciklusa).
Patients were randomised to receive one of the following neoadjuvant regimens for 4 cycles prior to surgery:
Bolnice so pred operacijo randomizirali v enega od naslednjih neoadjuvantnih režimov (prejele so 4 cikle):
Patients were randomised to receive one of three neoadjuvant regimens prior to surgery as follows:
Bolnice so pred operacijo randomizirali v enega od naslednjih treh neoadjuvantnih režimov:
Patients were randomised to receive placebo + MTX, Simponi 50 mg + MTX, Simponi 100 mg + MTX or Simponi 100 mg + placebo.
Bolnike so naključno razvrstili v več skupin: za prejemanje placeba in metotreksata, za prejemanje zdravila Simponi 50 mg in metotreksata, za prejemanje zdravila Simponi 100 mg in metotreksata ali pa za prejemanje zdravila Simponi 100 mg in placeba.
Patients were randomised to receive placebo + MTX, Simponi 50 mg + MTX, Simponi 100 mg + MTX or Simponi 100 mg + placebo.
Te bolnike so naključno razvrstili bodisi v skupino, ki bo prejemala placebo in metotreksat, zdravilo Simponi 50 mg in metotreksat, zdravilo Simponi 100 mg in metotreksat, ali pa zdravilo Simponi 100 mg in placebo.
Patients were randomized (1:1) to receive nintedanib 200 mg orally twice daily in combination with 75 mg/m2 of intravenous docetaxel every 21 days (n = 655) or placebo orally twice daily in combination with 75 mg/m2 of docetaxel every 21 days (n = 659).
Bolniki so bili randomizirani (1 : 1) na prejemanje nintedaniba po 200 mg peroralno dvakrat na dan v kombinaciji s 75 mg/m2 docetaksela intravensko vsakih 21 dni (n = 655) ali placeba peroralno dvakrat na dan v kombinaciji s 75 mg/m2 docetaksela vsakih 21 dni (n = 659).
Patients were randomized (1:1:1) to 1 of 3 treatment arms.
Bolnike so randomizirali (1:1:1) na 1 od 3 skupin terapije.
Patients were randomized 1:1 to receive either bendamustine (B) alone (n = 202) or Gazyvaro in combination with bendamustine (G+B) (n = 194) for 6 cycles, each of 28 days duration.
Bolnike so v razmerju 1:1 randomizirali na prejemanje bodisi samega bendamustina (B) (n = 202) bodisi zdravila Gazyvaro v kombinaciji z bendamustinom (G + B) (n = 194) za 6 28-dnevnih ciklusov.
Patients were randomized 1:1 to receive placebo + trastuzumab + docetaxel or Perjeta + trastuzumab + docetaxel.
Bolnike so randomizirali v razmerju 1 : 1 v skupino, ki je prejemala kombinacijo placeba + trastuzumaba + docetaksela in skupino, ki je prejemala kombinacijo zdravil Perjeta + trastuzumab + docetaksel.
Patients were randomized 1:1 to receive Tarceva 150 mg daily or up to 4 cycles of platinum based doublet chemotherapy.
Bolniki so bili randomizirani v razmerju 1 : 1 v skupino, ki je prejemala 150 mg zdravila Tarceva in v skupino, ki je prejemala kemoterapevtski dvojček na osnovi platine.
Patients were randomized 1:1 to receive Tarceva 150 mg or placebo orally once daily until disease progression.
Bolniki so bili randomizirani v razmerju 1 : 1 v skupino, ki je prejemala 150 mg zdravila Tarceva, in v skupino, ki je prejemala placebo, peroralno enkrat na dan, do napredovanja bolezni.
Patients were randomized 2:1 to the lenalidomide or the control arm.
Bolniki so bili randomizirani v skupino z lenalidomidom ali kontrolno skupino v razmerju 2:1.
Patients were randomized in a 1:1 fashion to treatment with either bosutinib 500 mg once daily or imatinib 400 mg once daily.
Bolnike so v razmerju 1:1 randomizirali bodisi v skupino, ki se je zdravila z 500 mg bosutiniba enkrat na dan, bodisi v skupino, ki se je zdravila s 400 mg imatiniba enkrat na dan.
Patients were randomized in a 1:1:1 ratio to one of 3 treatment arms.
Bolnike so randomizirali v razmerju 1:1:1 na eno od 3 skupin terapije.
Patients were randomized to one of three double-blind treatment groups to receive saxagliptin 5 mg and dapagliflozin 10 mg added to metformin, saxagliptin 5 mg and placebo added to metformin, or dapagliflozin 10 mg and placebo added to metformin.
Bolnike so randomizirali v eno od treh dvojno slepih terapevtskih skupin, tako da so prejemali 5 mg saksagliptina in 10 mg dapagliflozina, dodanih metforminu, ali 5 mg saksagliptina in placebo, dodana metforminu, ali 10 mg dapagliflozina in placebo, dodana metforminu.
Patients were randomized to placebo or sildenafil (20 mg three times a day) in combination with bosentan (62.5-125 mg twice a day).
Bolnike so randomizirali na placebo ali sildenafil (20 mg trikrat na dan) v kombinaciji z bosentanom (62,5–125 mg dvakrat na dan).
Patients were randomized to receive a subcutaneous maintenance regimen of either 90 mg ustekinumab every 8 weeks, 90 mg ustekinumab every 12 weeks or placebo for 44 weeks (for recommended maintenance posology, see section 4.2 of the STELARA Solution for injection (vial) and Solution for injection in pre filled syringe SmPC).
Bolnike so randomizirali, da so subkutano prejemali ustekinumab v odmerkih po 45 mg, 90 mg ali placebo v tednu 0 in 4 in nato na vsakih 12 tednov.
Patients were randomized to receive either pegylated interferon alfa-2b (100 or 150 µg /week based on weight) plus ribavirin (800-1,200 mg/day based on weight) or Viraferon (3 MIU TIW) plus ribavirin (800-1,200 mg/day based on weight).
Bolnike so naključno razporedili bodisi v skupino, ki je prejemala pegiliran interferon alfa-2b (v odmerkih 100 ali 150 µg/teden odvisno od telesne mase) z ribavirinom (v odmerku 800-1.200 mg/dan, odvisno od telesne mase) ali pa v skupino, ki je prejemala zdravilo Viraferon (3 m.i.e. trikrat na teden) z ribavirinom (v odmerku 800-1.200 mg/dan odvisno od telesne mase).
Patients were randomized to receive either ribavirin (800 mg/day) plus peginterferon alfa-2b (1.5 µg/kg/week) or ribavirin (800 mg/day) plus interferon alfa-2b (3 MIU TIW) for 48 weeks with a follow-up period of 6 months.
Bolnike so naključno razporedili bodisi v skupino, ki bo prejemala ribavirin (800 mg/dan) in peginterferon alfa-2b (1,5 µg/kg/teden), ali pa v skupino, ki bo prejemala ribavirin (800 mg/dan) in interferon alfa-2b (3 mio. i.e. trikrat na teden) v času 48 tednov, s 6 mesečnim spremljanjem.
Patients were randomized to receive either ribavirin (800-1,200 mg/day based on weight) plus peginterferon alfa-2b (100 or 150 µg/week based on weight) or ribavirin
Bolnike so naključno razporedili bodisi v skupino, ki bo prejemala ribavirin (800-1.200 mg/dan glede na telesno maso) in peginterferon alfa-2b (100 ali 150 µg/teden glede na telesno maso) ali pa ribavirin (800
Patients were randomized to stay on their treatment at the time of enrollment or to be switched to MIRCERA in order to maintain stable haemoglobin levels.
Bolnike so razvrstili tako, da so ostali na zdravljenju, ki so ga prejemali ob času vstopa v raziskavo ali pa so prešli na zdravilo MIRCERA, z namenom vzdrževati stabilno koncentracijo hemoglobina.
Patients were randomized to stay on their treatment at the time of enrollment or to be switched to MIRCERA in order to maintain stable haemoglobin levels.
Bolnike so razvrstili tako, da so ostali na zdravljenju, ki so ga prejemali v času vključevanja v raziskavo ali pa so prešli na zdravilo MIRCERA, z namenom vzdrževati stabilno koncentracijo hemoglobina.
Patients were randomly assigned to placebo, Simponi 50 mg and Simponi 100 mg and were allowed to continue concomitant DMARD therapy (MTX, SSZ and/or HCQ).
Te bolnike so naključno razporedili v skupine za prejemanje placeba, zdravila Simponi 50 mg ali zdravila Simponi 100 mg in so jim dovolili nadaljevati s sočasno terapijo DMARD (metotreksat, sulfasalazin in/ali hidroksiklorokvin).
Patients were randomly assigned to placebo, Simponi 50 mg, or Simponi 100 mg.
Vse bolnike so naključno razvrstili bodisi v skupino za placebo, zdravilo Simponi v odmerku 50 mg, ali zdravilo Simponi v odmerku 100 mg.